TKI-258 (Dovitinib)
-
Technical Data
Description
TKI-258 (Dovitinib) is an orally bioavailable FGFR3 inhibitor, which strongly binds to fibroblast growth factor receptor 3 (FGFR3) and inhibits its phosphorylation, which may result in the inhibition of tumor cell proliferation and the induction of tumor cell death.